-
Corcept Therapeutics NASDAQ:CORT Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing's syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.
Location: 149 Commonwealth Dr, California, 94025-1133, United States | Website: www.corcept.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
6.029B
Cash
380.3M
Avg Qtr Burn
N/A
Short % of Float
18.63%
Insider Ownership
11.52%
Institutional Own.
85.55%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Korlym® (Relacorilant) Details Hypercortisolism, Cushing’s syndrome | Phase 4 Data readout | |
Korlym® (Relacorilant) Details Hypercortisolism | NDA Acceptance for review | |
Korlym® (Relacorilant) Details Hypercortisolism, Cushing’s syndrome | NDA Submission | |
Relacorilant + Nab-paclitaxel Details Ovarian cancer, Cancer, Solid tumor/s Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Miricorilant Details Non-alcoholic steatohepatitis | Phase 2b Data readout | |
Relacorilant (GR antagonist) + Enzalutamide Details Cancer, Castration-resistant prostate cancer, Solid tumor/s, Prostate cancer | Phase 2 Data readout | |
Dazucorilant Details Amyotrophic lateral sclerosis | Phase 2 Data readout | |
Miricorilant Details Obesity, Antipsychotic-Induced Weight Gain | Phase 2 Update | |
Relacorilant + pembrolizumab Details Cancer, Adrenal cancer | Phase 1b Update | |
Relacorilant + Nab-paclitaxel Details Pancreatic cancer | Failed Discontinued |